Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]
Phase 2
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2007-03-12
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 49
- Registration Number
- NCT00424229
- Locations
- π«π·
Hopital Archet, Nice, France
π«π·CHRU Hurriez, Lille, France
π«π·CHU Angers, Angers, France
Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 45
- Registration Number
- NCT00411905
- Locations
- π«π·
CHU Angers, Angers, France
π«π·Hopital Avicenne, Bobigny, France
π«π·Institut Bergonie, Bordeaux, France
Β© Copyright 2025. All Rights Reserved by MedPath